Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival  by Newell, Pippa H. et al.
ORIGINAL ARTICLE
Multimodal treatment of unresectable hepatocellular carcinoma to
achieve complete response results in improved survival
Pippa H. Newell1–3, YingXing Wu4, Helena Hoen3, Richa Uppal5, John Tyler Thiesing6, Kevin Sasadeusz6,
Maria A. Cassera1,2, Ronald F. Wolf1,2, Paul Hansen1,2 & Chet W Hammill1,2
1Hepatobiliary and Pancreatic Surgery Program, Providence Cancer Center, 2Gastrointestinal and Minimally Invasive Surgery Division, The Oregon Clinic,
3Earle A. Chiles Research Institute, 4Providence Health System, 5The Portland Clinic, and 6Department of Radiology, Providence Portland Medical Center,
Portland, Oregon, USA
Abstract
Introduction: With technological advances, questions arise regarding how to best fit newer treatment
modalities, such as transarterial therapies, into the treatment algorithm for patients with hepatocellular
carcinoma (HCC).
Methods: Between 2005 and 2011, 128 patients initially treated with transarterial radioembolization or
chemoembolization using drug-eluting beads were identified. The response was graded retrospectively.
Toxicity was measured 1, 3, and 6 months after the first and last treatments.
Results: Sixty-five patients (53%) were advanced stage. Twenty patients (16%) had an initial complete
response, but with additional treatments, this was increased to 46 (36%). Patients with a complete
response as their best response to treatment had a median survival [95% confidence interval (CI)] of 5.77
(2.58, upper limit not yet reached) years, significantly longer than those whose best response was a partial
response, 1.22 (0.84, 2.06) years and those with stable disease as their best response, 0.34 (0.29, 0.67)
years. Repeated treatments did not increase toxicity.
Discussion: This retrospective review of patients treated for intermediate and advanced stage HCC
revealed a significant survival advantage in patients who achieved a complete response. These data
support use of a multi-modality approach to intermediate and advanced stage HCC, combining liver-
directed treatments as necessary to achieve a complete response.
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Introduction
Hepatocellular cancer (HCC) is the most common primary
cancer of the liver, and develops almost exclusively in the setting of
chronic liver damage. The most common causes are chronic infec-
tion with hepatitis B and cirrhosis secondary to hepatitis C or
alcohol consumption. Based on 2011 Surveillance Epidemiology
and End Results (SEER) data, the incidence of HCC tripled from
1975 to 2005, and although survival has improved slightly in the
last decade, only 26% of patients with disease confined to the
primary tumour site survive for 5 years.1 In patients diagnosed
after the disease has spread to the regional lymph nodes, 5-year
survival is 9% and decreases to 2.6% in patients with metastatic
disease.
The Barcelona Clinic Liver Cancer (BCLC) staging system
stratifies these patients into five stages and is frequently used to
determine prognosis and guide treatment.2 The majority of
patients present with multifocal disease, large tumours, extrahe-
patic disease or comorbidities such as liver failure which make
them poor candidates for surgical intervention (BCLC stage B, C,
or D). A 2010 meta-analysis looking at the natural history of HCC
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patients who receive only palliative treatment or placebo included
in randomized trials determined that 1-year survival for BCLC
stage B patients was 49.6%, compared with 25% for BCLC stage C
patients and 11% for BCLC stage D patients.3
For BCLC stage B patients, multiple transarterial treatments
have been developed in an attempt to extend survival and provide
palliation. The various transarterial therapies are difficult to
compare because of the lack of standardized treatment protocols,
although recent meta-analyses have shown them to be superior to
no treatment or systemic chemotherapy.4–6
More recently, embolic particles that slowly elute chemothera-
peutic agents (transarterial chemotherapy with drug-eluting
beads, termed here TACE/DEB), were introduced in an effort to
increase the time that the tumour is exposed to the chemotherapy.
For the treatment of HCC these beads are generally impregnated
with doxorubicin.7 PRECISION V, a randomized phase II trial of
conventional TACE with versus TACE/DEB, including intra-
hepatic doxorubicin in both treatment arms, showed improved
safety in the TACE/DEB arm and an improved response in
patients with advanced disease at 6 months.8
Investigators also began to use radioactive beads for
transarterial treatment of the tumour with localized radiation
therapy. Yttrium-90-impregnated beads (Y-90) are most com-
monly used for radioembolization, and results have been encour-
aging, showing efficacy in a range of tumours affecting the liver
including HCC.9 Based on the promising results, many centres
have extended the use of Y-90 to a subset of BCLC stage B and C
patients with diffusely infiltrative tumours, portal vein invasion
and even limited extrahepatic disease. Salem et al. performed a
comparative analysis of 463 patients treated with TACE or
radioembolization which showed no significant difference in the
median 5-year survival. They concluded that a randomized trial of
more than 1000 patients would be required to confirm statistical
equivalence between the treatment modalities.10
Although multiple trials have shown the different treatment
modalities to be effective, because of the similarities in efficacy, the
variability in treatment protocols and the continuous changes in
technology it will be challenging to prove superiority of either
modality. The following manuscript demonstrates that a signifi-
cant number of patients who were ultimately treated with both
Y-90 and TACE/DEB survived longer than predicted. Tumour-
and patient-specific variables that determine whether patients
benefit more from one therapy over the other were sought, with
the notion that the choice and order of therapies may affect out-
comes. To investigate this further, a retrospective review of all of
the patients treated for locally aggressive HCC was performed to
determine factors that correlate with response and survival.
Patients and methods
Between 2005 and 2011, all patients with HCCwho were treated at
Providence Portland and Providence St. Vincent Medical Centers
were identified. Patients were included if their first treatment for
HCC was either TACE/DEB or Y-90. In an attempt to provide an
unbiased comparison, patients who were treated with other forms
of transarterial chemoembolization, bland embolization or liver
transplantation were excluded. Patients who were initially treated
with TACE/DEB or Y-90 and had a response allowing an attempt
at curative treatment with radiofrequency ablation or liver resec-
tion were included. Data were collected on patient demographics,
tumour characteristics, procedural data and outcomes. Imaging
was reviewed retrospectively by a board certified interventional
radiologist and the treatment response was graded according to
the European Association for the Study of the Liver modified
Response Evaluation Criteria in Solid Tumors (RECIST), com-
monly referred to as the modified RECIST.11 Responses were
graded as a complete response (CR), partial response (PR), stable
disease (SD) or progressive disease (PD), each time a cross-
sectional contrast imaging study was performed during follow-up.
The best response was defined for each patient as the single best
response achieved at any point during follow-up. This study
protocol was approved by the Institutional Review Board, and
informed consent was obtained from all patients for participation
in the database.
HCC patients are reviewed at a multidisciplinary
hepatobiliary conference attended by surgeons, interventional
radiologists, hepatologists, medical oncologists and radiation
oncologists. While the group’s recommendations for treatment
were based on consensus guidelines,12 the type of liver-directed
therapy was not dictated by an algorithm at the time these
patients were enrolled and treated. The choice of either TACE/
DEB or Y-90 was made by the treating interventional radiologist
based on operator preference, previous local and systemic treat-
ments, tumor characteristics, and anatomical factors such as
potential for vascular shunting. In general, a total bilirubin
cut-off of 2 mg/dl was used for both modalities, and
radioembolization was preferred but not mandatory in patients
with large or infiltrative tumours, and those with portal vein
tumour thrombosis (PVTT).
Y-90 radioembolization was performed using Theraspheres
(MDS Nordion, Kanata, ON, Canada). Pre-treatment visceral
arteriography was performed to evaluate the vasculature, perform
coil embolization of any normal or aberrant visceral vessels to
prevent non-target embolization and determine the liver-to-lung
shunt ratio. This was performed with injection of Technetium
99-m microaggregated albumin into the right or left hepatic
arteries. Patients with shunts greater than 15% or a calculated
Y-90 dose greater than 30 Gray to the lung were excluded from
treatment with Y-90. Y-90 dose calculation was based on the body
surface area method as described previously.13 Calculated tissue
doses ranged from 80 to 120 Gray. Therapeutic Y-90 embolization
to the hepatic lobe harbouring the dominant tumour volume
was performed 2 weeks after mapping arteriography. Radio-
embolization was sometimes repeated in patients with bilobar
disease, who had the non-dominant lobe treated 4 weeks after the
first treatment, and rarely to retreat disease within the same lobe.
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Treatment with TACE/DEB was performed using standard
endovascular techniques. Chemoembolization was performed
almost exclusively with LC Beads (Biocompatibles, Farnham,
UK). Earlier patients in the period reviewed received a single vial
of larger beads (300–500 micron) and smaller doses (total
50 mg doxorubicin), whereas later patients received 2 vials of
smaller beads (100–300 micron) at higher doses (up to 100 mg
doxorubicin). The embolization endpoint was total dose delivery,
complete tumour devascularization on immediate post-
embolization angiography or stasis in subsegmental hepatic
arterial branches. Similar to Y-90, the hepatic lobe harbouring the
largest tumour burden was embolized first, followed by the less
effected side 4 weeks later. Transarterial embolization with bland
LC beads not containing doxorubicin was utilized to treat phrenic
arteries feeding the tumour when necessary.
With both modalities, patients generally received one or two
treatments based on their disease burden. The treatment response
was ideally evaluated 1 month after TACE/DEB and 3 months
after Y-90. Patients with a partial and complete response were
observed and monitored for disease progression using contrast
imaging at regular intervals. Both CT andMRI were used to assess
the response. The choice of imaging modality was made by the
treating physician and was based most often on the pre-treatment
imaging modality. At the time of disease progression, further
treatment was pursued based on the patient’s overall clinical
picture.
Statistical analysis
The date of death was obtained from the Social Security Death
Index. The Kaplan–Meier method was used to display overall
survival by best response and to calculate the median survival
times and confidence intervals (CI) for each response. However,
making statistical inference of survival by treatments from com-
parison of survival by response has been criticized because
‘response’ could be a marker for patients with a favourable prog-
nosis.10,14 Therefore, multivariate Cox Regression analysis was
used to assess whether response predicted survival independently
of patient baseline characteristics, with a response as a time-
dependent covariate. Variables included in the multivariate model
were selected using stepwise Akaike information criteria (AIC).
Response, treatment type (TACE/DEB, Y-90 or both) and the
number of treatments were all treated as time-dependent
covariates. Survival analysis was performed using STATA version
11.0 (StataCorp LP, College Station, TX, USA) and R 2.15 (http://
www.R-project.org).
Analysis of toxicity was performed on post-treatment biliru-
bin levels at 1, 3 and 6 months after the first and last HCC treat-
ments received. Subjects that received only one treatment (46/
128, 36%) are included in both analyses of first treatment and
analyses of last treatment. The sample size decreased over time
owing to mortality rates and time of last contact (see survival
curve in Fig. 1), thus to avoid potential bias in estimates from an
overarching model across time, separate analyses were per-
formed for each time point. Multivariate regression was used to
test bilirubin values across time, and multivariate logistic regres-
sion to test occurrence of any adverse event (AE) defined as bili-
rubin >3.6, international normalized ratio (INR) >2.3 or
albumin <2.0 based on grade 3 CTCAE definitions. Medians and
interquartile range (IQR), the 25th and 75th percentiles, were used
to describe the distribution of bilirubin values. SAS 9.3 was used
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Figure 1 Overall survival curves stratified by initial treatment modality (a) and best response to treatment (b). Numbers above the x-axis are
the number of patients currently at risk in each category. (a) The Kaplan–Meier method of survival analysis reveals no difference in survival
between patients treated initially with transarterial chemoembolization with drug-eluting beads (DEB) or transarterial radioembolization with
yttrium-90 (Y90). (b) Overall survival curves stratified by best response to treatment. The Kaplan–Meier method of survival analysis
demonstrates a significantly prolonged survival in patients who achieved a complete response to treatment as their best response as
measured by modified RECIST, as compared with those who only achieved a partial response or who had stable disease. CR, complete
response; PR, partial response; SD, stable disease
HPB 2015, 17, 454–460 ª 2015 International Hepato-Pancreato-Biliary Association
456 HPB
for AE and bilirubin analysis (SAS Institute Inc, Cary, North
Carolina).
Results
One hundred forty-one patients with HCC who received TACE/
DEB or Y-90 at some point during their treatment were identified.
Thirteen patients were excluded, nine who were not initially
treated with TACE/DEB or Y-90, three who had subsequent
treatments with transarterial chemoembolization or bland
embolization, and one patient who was treated as a bridge to liver
transplant. Patient demographics and tumour characteristics of
the remaining 128 patients are summarized in Table 1. The
median time between treatment and first evaluation of response
was 57 (range: 20–160) days after Y-90 and 36 (range: 3–391) days
after TACE/DEB.
Fifty-six patients were initially treated withY-90 and 23 of those
went on to treatment with additional modalities. Eighteen
patients went on to treatment with TACE/DEB, 3 patients went on
to RFA and of those 18 patients, 5 patients were subsequently
treated with both RFA and TACE/DEB.
In 72 patients TACE/DEB was used as the initial treatment.
Twenty-one of these patients had additional treatments. Seven
patients had second-line treatment with Y-90 only, 8 had RFA, 3
had hepatic resection, 1 had both Y-90 and RFA, 1 had both Y-90
and resection and 1 had RFA and a resection.
The response to the initial treatment regimen and best response
after any number of treatments are summarized in Table 2. There
was not a statistical difference in survival between patients who
were treated initially with either TACE/DEB or Y-90 (Fig. 1a).
Patients with a complete response as their best response to treat-
ment had a median survival (95% CI) of 5.77 (2.58, the upper
limit has not yet been reached) years, significantly longer than
those whose best response was a partial response, 1.22 (0.84, 2.06)
years and those with stable disease as their best response, 0.34
(0.29, 0.67) years (Fig. 1b). The presence of ascites at baseline, low
albumin, BCLC stage C or D, large lesions (greater than 5 cm or
diffuse) and a lack of a complete response were all associated with
decreased survival on multivariate Cox Regression with time-
dependent covariates. The hazard ratios and P-values are summa-
rized in Table 3.
The median (IQR) baseline bilirubin was 1.0 mg/dl (0.7, 1.6).
At 1, 3 and 6 months after the first HCC treatment, the median
bilirubin levels ranged from 1.1 (0.7, 1.8) to 1.5 mg/dl (0.8, 2.2).At
1, 3 and 6 months after the last treatment, the median bilirubin
levels ranged from 1.3 (0.8, 2.0) to 1.9 mg/dl (1.0, 3.5). Multivari-
ate regression after the last treatment showed no significant effect
of the number of treatments (1–6) at 1, 3 and 6 months post-
treatment (P = 0.264, 0.394, 0.464) after controlling for baseline
bilirubin, baseline portal venous tumor thrombosis (PVTT),
having received TACE/DEB and/or Y-90, and sorafenib (Table S1).
Baseline bilirubin had a significant positive association with post-
treatment levels at all time points (P < 0.001 at 1 month, P = 0.002
at 3 months and P = 0.042 at 6 months). None of the other
covariates had a significant effect on follow-up bilirubin. Simi-
larly, after the first HCC treatment, the baseline bilirubin was
positively associated with elevations in 1, 3 and 6 month bilirubin
levels (P < 0.001,P < 0.001,P = 0.001) after controlling for baseline
PVTT and the first type of treatment (TACE/DEB or Y-90). PVTT
and type of treatment were not significant.
Table 4 shows the per cent of patients that had AE grade 3 levels
of bilirubin, INR and albumin at 1, 3, and 6months after their first
Table 1 Patient demographics and tumour characteristics
Total 128 (100%)
Female 27 (21%)
Mean age ± SD (years) 64 ± 11
Number of tumours
1 67 (52%)
2 26 (20%)
3 9 (9%)
4 4 (3%)
>4 22 (17%)
Median size of largest tumour (cm) 5.3
-Interquartile range 3.1–6.9
Ascites 35 (29%)
Portal vein thrombosis 31 (24%)
Bilobar disease 36 (29%)
Extrahepatic disease 11 (9%)
BCLC Stage
B 56 (46%)
C 65 (53%)
D 2 (1.6%)
Child–Pugh
A 91 (69%)
B 41 (30%)
C 2 (1.5%)
Median MELD 9
-Interquartile range 7–11
Median AFP (IU/ml) 24
-Interquartile range 7–256
Mean albumin ± SD (g/dl) 3.4 ± 0.6
ECOG performance status
0 72 (52%)
1 60 (43%)
2 7 (5.0%)
Median number of HCC treatments 2
-Range 1–6
Received sorafenib 22 (17%)
BCLC, Barcelona Clinic Liver Cancer; MELD, model for end-stage liver
disease; ALF, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology
Group; HCC, hepatocellular carcinoma.
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and last HCC treatment. One month after the first treatment,
9.6% (11/115) patients had AEs, and 1 month after the last treat-
ment, 12.4% (13/105) had AEs. In both cases, rates approximately
doubled from the 1-month rate at 3 and 6 months. Of the factors
tested, only PVTT at baseline was significant at 6 months post last
treatment. PVTT was associated with 71⁄2 times the odds of having
an AE [P = 0.037, 95% CI (1.1, 48.9)].
Discussion
The most recent American Association for the Study of Liver
Diseases (AASLD) guidelines and the current BCLC staging
system recommend TACE as a first-line non-curative therapy for
patients with intermediate stage HCC (BCLC stage B).12 Recent
publications speak to the safety, tolerability and efficacy of Y-90
radioembolization and TACE/DEB for patients with inoperable
HCC.8,9With these technological advances, questions arise regard-
ing how to best fit these and other emerging treatments such as
stereotactic body radiation therapy into the HCC treatment
algorithm.
Data for this study were collected from 128 patients between the
years 2005 and 2011. Patients that had a complete response to
transarterial treatment as their best treatment had a significantly
longer overall median survival compared with those that had a
partial response, and with those who had stable disease. Multiple
studies have shown that improved survival in HCC is associated
with a response to transarterial treatment based on modified
RECIST.10,14 However, as outlined by Anderson et al.,15,16 these
papers suffer from a bias introduced by dividing patients based on
response and then statistically comparing their survival. The
patients who have the shortest survival, those that do not survive
to the evaluation of first response, are arbitrarily assigned to a
group, shortening the overall survival of that group. For this
reason, analyses substituting the tumour response as a surrogate
of survival are not commonly reported in the oncology literature.
Anderson et al. recommend using either the landmark method, in
which patients who die before the ‘landmark time’ are excluded
from analysis, or making a response status a time-dependent
covariate. In the analysis presented here, the latter method was
chosen, and therefore the response was treated as a time-
dependent variable that allows for changes in responses over time.
During the period studied, the protocols at the institutions
under study evolved. Initially, patients with a partial or complete
response were observed and monitored for disease progression.
Y-90 was commonly used as a first-line treatment for
unresectable HCC patients with disease confined to the liver.
With the development of TACE/DEB, the treatment team
described here migrated towards its use as first-line therapy
except for patients with portal vein involvement or those with
bulky, diffuse disease. This was based mostly on the logistical
complexities and cost of treatment with Y-90.17,18 Interim evalu-
ation of the data suggested that repeating treatments or alternat-
ing modalities as necessary to achieve a complete response was a
superior approach to simple observation after a partial response.
The current algorithm has been changed accordingly: patients
whose first follow-up imaging demonstrates stable disease or a
partial response are re-treated immediately, with additional
TACE/DEB, ablation, resection or with Y-90 depending on
factors individual for each case. The data presented here shows
that 20/128 patients (16%) had an initial complete response, but
with additional treatments, this was increased to 46/128 (36%).
This compares favourably to the complete response rate of 26.9%
seen in the PRECISION V study, a large prospective randomized
trial in which TACE/DEB was administered to BCLC A and B
stage patients.19 Response rates in the PRECISION trial were
based on EASL guidelines, which often underestimate the
response compared with the modified RECIST. A more recent
study measuring response to TACE/DEB by modified RECIST
criteria reported a complete response rate of 20% in patients
with BCLC Stage A, B and C disease. The median survival in the
patients with a complete response had not been reached at the
end of the study period, similar to the results presented here. The
median survival of all responders in that trial was 28 months,
versus 9.1 months in the non-responders.20
It is worth noting that 65 out of the 128 patients (53%)
included in this study were BCLC stage C. In formalized treatment
guidelines issued by national and international committees such
as AASLD and EASL, transarterial treatments are only recom-
mended for BCLC stage B patients. The current recommendation
for BCLC stage C patients is sorafenib, a systemic targeted therapy
which provides a median survival of 10.7 months.21 However,
many centres treat patients with limited extrahepatic disease
and/or portal vein thrombosis with liver-directed therapy in light
of data from large cohort studies which demonstrate favourable
response and survival rates in these selected patients with
advanced HCC when compared with historical controls treated
with systemic therapy.6,8,13 To address this discrepancy between
guidelines and current clinical practice, there are several ongoing
multi-centre randomized trials comparing transarterial
radioembolization to systemic treatment for patients with
advanced HCC (clinicaltrials.gov).
Studies such as this are limited by their retrospective design, but
until data from prospective randomized studies are available, the
data support the following conclusions: neither of the two treat-
Table 2 Response to treatment based on modified response evalu-
ation criteria in solid tumors (RECIST)
Type of response
N = 128 patients
Initial response
N (%)
Best response
N (%)
Complete response 20 (15.6%) 46 (35.9%)
Partial response 75 (58.6%) 53 (41.4%)
Stable disease 6 (4.7%) 29 (22.6%)
Progressive disease 17 (13.3%) –
Death prior to
post-treatment imaging
10 (7.8%) –
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ment types (TACE/DEB or Y-90) compared is clearly superior to
the other; they can be used sequentially over time to achieve a
complete response; and treatments can be repeated without
accruing additional morbidity. Based on the analysis here, it
appears that it is the successful achievement of a complete
response, not the type of liver directed therapy performed, which
determines survival. Although this study did not demonstrate a
clear advantage of starting with either TACE/DEB or Y-90, future
studies will be necessary to understand whether there is a sequen-
tial advantage to using one or the other modality first.
Table 3 Multivariate Cox regression analysis of factors associated with overall survival
Multivariate survival
(N = 128 patients)
Comparison Hazard ratio
(95% CI)
P
Ascites at baseline No ascites 2.21 (1.10, 4.47) 0.027
Albumin Unit = 1 g/dl 0.37 (0.22, 0.64) <0.001
BCLC Stage C or D BCLC Stage B 4.11 (2.11, 8.01) <0.001
Largest lesion size > 5 cm (including diffuse) Largest lesion Size < 5 cm 2.48 (1.31, 4.67) 0.005
TACE/DEB Y90 alone 0.66 (0.37, 1.17) 0.115
Y90 and TACE/DEB Y90 alone 1.09 (0.44, 2.66) 0.859
Number of treatments Unit = 1 treatment 0.73 (0.52, 1.04) 0.079
Progressive disease Complete Response 7.62 (2.21, 26.3) <0.001
Stable disease Complete Response 5.33 (1.42, 20.0) 0.013
Partial response Complete Response 3.66 (1.01, 13.3) 0.048
The bold text indicates a significant value.
BCLC, Barcelona Clinic Liver Cancer; TACE/DEB, transarterial chemotherapy with drug-eluting beads.
Table 4 Multivariate logistic regression of factors associated with bilirubin, international normalized ratio (INR) and albumin adverse events
based on CTCAE (v3)
MVA Biochemical
AE, N (%)
Factor Comparison Odds ratio
(95% CI)
P
After first treatment
1 month 11/115 (9.6%) PVTT No PVTT 1.20 (0.29, 4.95) 0.804
1st Tx Y90 1st Tx DEB 0.50 (0.12, 2.02) 0.330
3 months 13/72 (18.1%) PVTT No PVTT 1.09 (0.26, 4.60) 0.904
1st Tx Y90 1st Tx DEB 0.74 (0.20, 2.71) 0.652
6 months 7/40 (17.5%) 1st Tx Y90 1st Tx DEB 1.73 (0.32, 9.17) 0.523
After last treatment
1 month 13/105 (12.4%) PVTT No PVTT 2.44 (0.67, 8.86) 0.175
Number of Txs Unit = 1 0.54 (0.25, 1.16) 0.114
Both Y90 and DEB DEB only 0.53 (0.05, 5.96) 0.552
Y90 only DEB only 0.47 (0.11, 1.96)
3 months 21/77 (27.3%) PVTT No PVTT 1.17 (0.36, 3.78) 0.796
Sorafenib No Sorafenib 0.46 (0.09, 2.51) 0.374
Number of Txs Unit = 1 0.75 (0.43, 1.31) 0.317
Both Y90 and DEB DEB only 1.08 (0.22, 5.26) 0.515
Y90 only DEB only 0.48 (0.13, 1.76)
6 months 11/51 (21.6%) PVTT No PVTT 7.45 (1.13, 48.97) 0.037
Sorafenib No Sorafenib 2.51 (0.39, 15.95) 0.330
Number of Txs Unit = 1 0.85 (0.46, 1.58) 0.607
Both Y90 and DEB DEB only 0.28 (0.03, 2.66) 0.427
Y90 only DEB only 0.34 (0.04, 2.68)
The bold text indicates a significant value.
MVA, multivariate analysis; CI, confidence interval.
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Conclusion
This retrospective review of all patients treated for intermediate
and advanced stage hepatocellular cancer at two institutions
between 2005 and 2011 revealed a significant survival advantage
in patients who achieved a complete response by modified
RECIST criteria. Ultimately a complete response was obtained in
46 out of 128 (36%) of patients using multiple-modality treat-
ment, including Y-90, TACE/DEB, and relatively limited use of
RFA and hepatic resection. Superiority of one modality over the
other was not demonstrated. Successful achievement of a com-
plete response impacts the length of survival more than the type of
liver-directed therapy performed.
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